Histone modifications are implicated in cancer and HDAC inhibitors (HDACis) can be useful to treat hematological malignancies, including leukemia, B-cell lymphoma, virus-associated tumors, and multiple myeloma. This evidence concerns the gene HDAC9 and leukemia.